Smart, Safe, Saxy Choice: Why FDA Selected Onglyza for Mini-Sentinel Project
This article was originally published in RPM Report
Executive Summary
FDA has a lot at stake in the first tangible drug surveillance project through Mini-Sentinel and a lot of audiences to please: Congress, regulated industry, academia, the drug safety community, media and general public. Here is how FDA explained the choice of saxagliptin as the first focus of the project.
You may also be interested in...
CV Outcomes Trials In Diabetes: First Results Suggest “Goalpost” Model Here To Stay
The first FDA advisory committee review of post-marketing cardiovascular outcomes trials conducted under the CV safety requirements imposed by the agency in 2008 ended with clear votes in favor of new warnings for the affected products – and a less explicit but no less clear endorsement of the approach spelled out in the guidelines.
Bristol-Myers Squibb/AstraZeneca Onglyza is Guinea Pig for FDA Mini-Sentinel Post-Market Surveillance
FDA’s Congressionally-mandated active surveillance system, Sentinel, is ready for shakedown cruises in 2011. One of the first projects will be a close examination of real-world experience and cardiovascular events associated with saxagliptin. That’s a dubious distinction for BMS/AZ, the co-marketers of Onglyza–but it also sets up a new dynamic that all sponsors should watch.
GSK's Dan Troy: Mixed Sentiments on Sentinel
FDA has made great progress on its active surveillance project Sentinel. GSK’s top lawyer raises some tough questions for the drug industry to consider as the program advances. Here is an excerpt from his remarks to the third annual workshop on Sentinel, hosted by the Engelberg Center for Health Care Reform at Brookings.